A Case History of a Rheumatologist With Relapsed Leukemia and Triple-Negative Breast Cancer
source: pixabay.com

A Case History of a Rheumatologist With Relapsed Leukemia and Triple-Negative Breast Cancer

Breast cancer is a result of a cell in the breast mutating and multiplying rapidly. There are over 275,000 occurrences of breast cancer in the U.S. each year. However, new…

Continue Reading A Case History of a Rheumatologist With Relapsed Leukemia and Triple-Negative Breast Cancer
Acute Myeloid Leukemia (AML): The Fine Line Between Proliferation of AML Cells and Death Of AML Cells
source: pixabay.com

Acute Myeloid Leukemia (AML): The Fine Line Between Proliferation of AML Cells and Death Of AML Cells

According to a recent article in MedicalXpress, researchers led by professor of medicine Dr. Jing Chen uncovered new data showing how acute myeloid leukemia (AML) becomes active and progresses. The…

Continue Reading Acute Myeloid Leukemia (AML): The Fine Line Between Proliferation of AML Cells and Death Of AML Cells
Phase 3 Data Available on Pevonedistat for AML, MDS, CMML
PhotoLizM / Pixabay

Phase 3 Data Available on Pevonedistat for AML, MDS, CMML

In the Phase 3 PANTHER clinical trial, also known as the Pevonedistat-3001 study, researchers were evaluating pevonedistat in conjunction with azacitidine for patients with acute myeloid leukemia (AML), myelodysplastic syndromes…

Continue Reading Phase 3 Data Available on Pevonedistat for AML, MDS, CMML
The FDA Approves An Expanded Chemotherapy Treatment For Acute Myeloid Leukemia to Include Children
source: pixabay.com

The FDA Approves An Expanded Chemotherapy Treatment For Acute Myeloid Leukemia to Include Children

  Cancer Network recently reported that Jazz Pharmaceuticals’ Vyxeos was approved by the FDA to treat therapy-related pediatric patients one year or older who were newly diagnosed with acute myeloid…

Continue Reading The FDA Approves An Expanded Chemotherapy Treatment For Acute Myeloid Leukemia to Include Children
First Patient Dosed in CA-4948 Trial for Hematologic Malignancies
source: pixabay.com

First Patient Dosed in CA-4948 Trial for Hematologic Malignancies

The first patient has been dosed in a Phase 1 clinical trial, which is exploring Curis Inc.'s CA-4948 in conjunction with ibrutinib for hematologic malignancies. Examples of hematologic malignancies include…

Continue Reading First Patient Dosed in CA-4948 Trial for Hematologic Malignancies
NMPA Grants Conditional Approval to XOSPATA for FLT3mut+ AML
rawpixel / Pixabay

NMPA Grants Conditional Approval to XOSPATA for FLT3mut+ AML

  In an early February press release, pharmaceutical company Astellas Pharma Inc. ("Astellas") shared that XOSPATA (gilteritinib) was given conditional approval in China for the treatment of patients with FLT3-mutated…

Continue Reading NMPA Grants Conditional Approval to XOSPATA for FLT3mut+ AML
Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia May Increase with PARP Inhibitors
source: pixabay.com

Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia May Increase with PARP Inhibitors

Poly (ADP-Ribose) polymerase inhibitors (PARP inhibitors) are used to treat neoplasms. They are frequently used as a therapy for ovarian cancer. A recent study has attempted to detect the possibility…

Continue Reading Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia May Increase with PARP Inhibitors

Sabatolimab Can Be Added Safely to Hypomethylating Agents in the Treatment of MDS and AML

Dr. Andrew Brunner, an oncologist at Massachusetts Cancer Center was recently interviewed by Targeted Oncology. The discussion centered around a phase 1b clinical trial (NCT03066648) investigating sabatolimab together with hypomethylating…

Continue Reading Sabatolimab Can Be Added Safely to Hypomethylating Agents in the Treatment of MDS and AML
Experimental Treatment Could be Useful in Numerous Rare and Deadly Cancers
source: pixabay.com

Experimental Treatment Could be Useful in Numerous Rare and Deadly Cancers

While novel treatments have been rapidly emerging onto the drug scene, new treatment options for pancreatic cancer have fallen behind. But now, according to OncLive’s interview with Dr. P.A. Philip,…

Continue Reading Experimental Treatment Could be Useful in Numerous Rare and Deadly Cancers
Phase 1b Data Shows Magrolimab Clinical Response for AML
source: pixabay.com

Phase 1b Data Shows Magrolimab Clinical Response for AML

In early December 2020, biopharmaceutical company Gilead Sciences, Inc. ("Gilead") shared updated results from a Phase 1b clinical trial evaluating magrolimab for patients with treatment-naïve acute myeloid leukemia (AML). Generally,…

Continue Reading Phase 1b Data Shows Magrolimab Clinical Response for AML
A New Treatment for BPDCN is on Track for EU Approval
source: pixabay.com

A New Treatment for BPDCN is on Track for EU Approval

According to a story from PR Newswire, the pharmaceutical and diagnostics company The Menarini Group recently announced that its drug tagraxofsup (marketed as Elzonris) has a received a positive opinion…

Continue Reading A New Treatment for BPDCN is on Track for EU Approval
Astellas Pharma Provides Help, Guidance, and Hope for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Andrew Krivoshik, M.D., Ph.D., was promoted to senior vice president and Oncology Therapeutic Area Head on April 1, 2019

Astellas Pharma Provides Help, Guidance, and Hope for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Astellas Pharma, headquartered in Northbrook, Illinois presents its Be R/Ready program to promote patient-physician communication as well as other valuable and informative resources. Their program centers around patients with relapsed…

Continue Reading Astellas Pharma Provides Help, Guidance, and Hope for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)